Specifically, the reported data were compared regarding CAR‐T therapeutic efficacy (CR, PFS and OS) of wild‐type and TP53 m groups between B cell lymphoma and B cell leukaemia. This evidence concerns the gene TP53 and B-cell non-Hodgkin lymphoma.